Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?



Rating:

Share or cite this content

Citations should be made in the following way:
P. Nair (Hamilton (ON), Canada). Who should receive which biologic and why? Current and future approaches in severe asthma patients. Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?

Member's Comments

No comment yet.

Related content which might interest you: Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 What is the scientific and clinical rationale? Triple therapy in COPD patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 How are we going to treat IPF patients in the future? Source: Annual Congress 2013 –The future of IPF: current mysteries and challenges Year: 2013 Recommended new therapies for severe asthma and the future Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 Can asthma patients cope with new treatment regimens in Ukraine? Source: Eur Respir J 2003; 22: Suppl. 45, 409s Year: 2003 What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance Source: ERJ Open Res, 7 (1) 00497-2020; 10.1183/23120541.00497-2020 Year: 2021 What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement Source: Eur Respir J, 52 (5) 1801261; 10.1183/13993003.01261-2018 Year: 2018 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Emerging biologic approaches for the treatment of difficult to control asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 The prevalence of severe asthma in specialist care –identifying eligible candidates for biological therapies Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Which are the best methods to manage COPD patients in the post-COVID era? Source: Virtual Congress 2021 – Part I: restarting COPD care in the post-COVID era Year: 2021 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009